Sanara MedTech Inc. reported second quarter 2026 financial results with net revenue increasing 9% to $28.1 million from $25.8 million in the prior year period. Gross profit rose to $26.2 million, or 93% of net revenue, while operating income decreased to $1.8 million from $2.5 million. The company reported a net loss from continuing operations of $0.4 million, or $0.05 per diluted share, compared to net income of $0.5 million in the same quarter last year. Adjusted EBITDA increased 7% to $5.0 million. For the first six months of 2026, net revenue grew 14% to $55.9 million and adjusted EBITDA reached $9.3 million. The company holds $15.4 million in cash and $46.5 million in long-term debt as of June 30, 2026. Management announced a transformational agreement to be acquired by MIMEDX Group Inc., pending customary closing conditions. Sanara MedTech is a medical technology company focused on developing and commercializing surgical products for the tissue repair market.

Sanara MedTech Inc. entered into a definitive Agreement and Plan of Merger with MiMedx Group, Inc., under which MiMedx will acquire Sanara in an all-stock and cash transaction. Upon closing, each share of Sanara common stock will be converted into $33.00 in cash plus 0.4735 shares of MiMedx common stock, representing a total consideration value of approximately $35.00 per share based on recent trading prices. The merger requires approval by Sanara's stockholders and customary regulatory clearances, including Hart-Scott-Rodino waiting periods. Specified stockholders holding approximately 38.9% of voting power have agreed to vote in favor of the transaction. If terminated under specific circumstances, Sanara must pay a $9,660,336 termination fee, while MiMedx owes $22,540,785 if it fails to consummate. This filing corrects an initial reporting error regarding these termination fee amounts. Sanara MedTech Inc. operates in the medical technology industry, specializing in the processing and distribution of amniotic membrane products for regenerative medicine.

Sanara MedTech Inc. entered into a definitive Agreement and Plan of Merger with MiMedx Group, Inc., under which MiMedx will acquire Sanara in an all-stock and cash transaction valued at approximately $350 million. Each outstanding share of Sanara common stock will be converted into the right to receive $33.00 in cash and 0.4735 shares of MiMedx common stock, representing a total consideration of $35 per share. This mix includes a cash component and a stock component valued at $2.00 per share based on MiMedx's five-day average closing price. The Sanara Board unanimously recommended the transaction, which is expected to close by the end of 2026 subject to shareholder approval, regulatory clearances including Hart-Scott-Rodino, and other customary conditions. MiMedx intends to finance the cash portion using existing cash and a new $300 million term loan from Hayfin Capital Management. The combined entity is projected to generate over $400 million in 2027 revenue with an adjusted EBITDA margin exceeding 20%. Sanara MedTech Inc. operates in the medical technology industry, developing and commercializing regenerative products for surgical markets.

On June 4, 2026, Sanara MedTech Inc. held its Annual Meeting of Shareholders, where shareholders approved the election of nine directors to the Board of Directors, the ratification of of Weaver and Tidwell, L.L.P. as the company's independent registered public accounting firm, and advisory votes on executive compensation. A total of 6,701,593 shares were present. Sanara MedTech Inc. develops and manufactures medical technology solutions for the treatment of skin and skin-related disorders.